BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mannucci P, Cugno M. The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring. Thrombosis Research 2015;136:851-4. [DOI: 10.1016/j.thromres.2015.09.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Frazer-abel A, Sepiashvili L, Mbughuni M, Willrich M. Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation. Elsevier; 2016. pp. 1-75. [DOI: 10.1016/bs.acc.2016.06.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
2 Caeiro Alves F, Aguiar R, Pessegueiro P, Pires C. Thrombotic microangiopathy associated with Mycoplasma pneumoniae infection. BMJ Case Rep 2018;2018:bcr-2017-222582. [PMID: 29550758 DOI: 10.1136/bcr-2017-222582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Fidalgo T, Martinho P, Pinto CS, Oliveira AC, Salvado R, Borràs N, Coucelo M, Manco L, Maia T, Mendes MJ, Del Orbe Barreto R, Corrales I, Vidal F, Ribeiro ML. Combined study of ADAMTS13 and complement genes in the diagnosis of thrombotic microangiopathies using next-generation sequencing. Res Pract Thromb Haemost 2017;1:69-80. [PMID: 30046676 DOI: 10.1002/rth2.12016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
4 Joseph A, Rafat C, Zafrani L, Mariani-Kurkdjian P, Veyradier A, Hertig A, Rondeau E, Mariotte E, Azoulay E. Early Differentiation of Shiga Toxin-Associated Hemolytic Uremic Syndrome in Critically Ill Adults With Thrombotic Microangiopathy Syndromes. Crit Care Med 2018;46:e904-11. [PMID: 29979220 DOI: 10.1097/CCM.0000000000003292] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
5 Oh J, Oh D, Lee SJ, Kim JO, Kim NK, Chong SY, Huh JY, Baker RI; Korean TTP Registry Investigators. Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura. Blood Res 2019;54:218-28. [PMID: 31730685 DOI: 10.5045/br.2019.54.3.218] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
6 Singh K, Nadeem AJ, Doratotaj B. A rare case of thrombotic microangiopathy triggered by acute pancreatitis. BMJ Case Rep 2017;2017:bcr-2016-218581. [PMID: 28512098 DOI: 10.1136/bcr-2016-218581] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
7 Clark WF, Huang SS, Walsh MW, Farah M, Hildebrand AM, Sontrop JM. Plasmapheresis for the treatment of kidney diseases. Kidney International 2016;90:974-84. [DOI: 10.1016/j.kint.2016.06.009] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 5.2] [Reference Citation Analysis]
8 Chaturvedi S, Dhaliwal N, Hussain S, Dane K, Upreti H, Braunstein EM, Yuan X, Sperati CJ, Moliterno AR, Brodsky RA. Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome. Blood Adv 2021;5:1504-12. [PMID: 33683339 DOI: 10.1182/bloodadvances.2020003175] [Reference Citation Analysis]
9 Joseph A, Cointe A, Mariani Kurkdjian P, Rafat C, Hertig A. Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review. Toxins (Basel) 2020;12:E67. [PMID: 31973203 DOI: 10.3390/toxins12020067] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 16.0] [Reference Citation Analysis]
10 Mariotte E, Azoulay E, Galicier L, Rondeau E, Zouiti F, Boisseau P, Poullin P, de Maistre E, Provôt F, Delmas Y, Perez P, Benhamou Y, Stepanian A, Coppo P, Veyradier A. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. The Lancet Haematology 2016;3:e237-45. [DOI: 10.1016/s2352-3026(16)30018-7] [Cited by in Crossref: 113] [Cited by in F6Publishing: 40] [Article Influence: 18.8] [Reference Citation Analysis]
11 Castelli R, Lambertenghi Delilliers G, Gidaro A, Cicardi M, Bergamaschini L. Complement activation in patients with immune thrombocytopenic purpura according to phases of disease course. Clin Exp Immunol 2020;201:258-65. [PMID: 32515487 DOI: 10.1111/cei.13475] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
12 Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ; Conference Participants. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2017;91:539-51. [PMID: 27989322 DOI: 10.1016/j.kint.2016.10.005] [Cited by in Crossref: 256] [Cited by in F6Publishing: 226] [Article Influence: 42.7] [Reference Citation Analysis]